Novocardia™ Named Among New York City’s Top 101 Health Care Companies and Startups of 2021

Company Recognized for Leading Innovation in Cardiovascular Disease Care with Value-Based Care Delivery Platform

    NEW YORK, Nov. 4, 2021— Novocardia, a value-based cardiovascular disease care delivery platform, today announced that it has been named one of the ‘101 Top New York City Health Care Companies and Startups of 2021′ by

    The list features NYC-based health care companies and startups chosen by industry professionals for exceptional performance in innovation, growth, management, and societal impact. From cutting-edge startups to established brands, Novocardia joins the ranks of companies like Peloton, Cedar, Spring Health, LetsGetChecked, Oscar Health, Spring Health and Zocdoc, bringing innovative ideas and products to market, delivering exceptional growth, and addressing important societal challenges.

    “Novocardia is honored to be named one of the top health care companies in New York City by, as we work to transform how cardiovascular disease care is delivered in the United States,” said Daniel Blumenthal, MD, MBA, Chief Executive Officer of Novocardia.

    “Cardiovascular disease is the single largest driver of health care spending in the United States, and accounts for approximately $320 billion in direct medical spending each year. We are focused on helping cardiologists to provide better care at lower cost and improving access to high quality cardiovascular disease care.”*

    Founded in 2020 by two cardiologists – Dr. Dan Blumenthal and Dr. Julius Torelli, FACC – Novocardia is committed to building a network of leading cardiologists and investing in their practices so that they can grow and adapt to changes in the health care landscape, including the shift to fee-for-value reimbursement models. Novocardia is focused on improving patient quality and outcomes through proactive and prevention-focused care, a proprietary actuarial and quality-focused analytics platform, and aligned partnerships with health plans and referral partners.

    “As Novocardia continues to expand in 2022, the key to our success remains the same – putting cardiologists, and their patients, at the center of care,” said Dr. Torelli, Novocardia’s Chief Medical Officer. “We invest in and partner with cardiologists in an increasingly complex care delivery and payment environment. With our support, cardiologists can succeed at delivering high-quality, high-value care that benefits patients, as well as health plans, primary care groups, and other referral sources.”


    Founded in 2020, Novocardia is on a mission to transform the delivery of cardiovascular care for all by building the national cardiovascular network of choice for high-quality, high-value care. Novocardia is committed to putting cardiologists, and their patients, at the center of care by investing in our partner practices, deploying purpose-built data and analytics tools to improve patient outcomes, and enabling our partners to transition more successfully to value-based care. To learn more about Novocardia, please visit


    Annually, awards the most successful startups in the U.S. with its lists featuring companies who are pushing the limits of innovation to solve critical problems and challenges. Created by Fupping LTD, a London-based media company, the mission of is to promote the greatest American companies, businesses and innovations on the global stage boosting inbound investment by addressing the information asymmetry between small innovative startups and institutional investors.


    * Sources: United States Centers for Disease Control. Available at: and

    We're Expanding Our Reach

    Novocardia is now a division of Cardiovascular Associates of America

    My Cardiologist Launches
    The Women’s Heart Health Program

    New program offers comprehensive prevention services, screenings, diagnostics and treatment for the number one cause of death and illness in all women

    Novocardia™ Cardiologist Co-Authors
    JAMA Study on Familial Idiopathic Dilated

    Dr. Javier Jimenez of My Cardiologist is a researcher with a national consortium studying DCM, a heart muscle disease that’s a leading cause of heart transplantation

    Novocardia™ CEO Dan Blumenthal
    Shares His Vision for the Future
    of Cardiovascular Care with
    Gist Healthcare Daily

    The shift toward more outpatient services presents growth opportunities for cardiology practices

    Novocardia™ Launches Groundbreaking,
    Value-Based Heart Failure Management
    Program to Improve Patient Outcomes
    and Reduce Hospitalizations

    The heart failure program is a new model for cardiology practices in managing heart failure, starting with patients in Northeast Florida

    Novocardia™ Announces
    Partnership with My Cardiologist

    New Collaboration Aims to Expand Access to High-Quality, High-Value
    Cardiovascular Care in South Florida

    Medicare Advantage for All

    A Potential Path to Universal Coverage

    Novocardia™ Recognized as a Rising
    Disruptor by Bernstein in U.S. Health
    Care Services

    Novocardia Joins List of Fast-Growing Private Companies Transforming Health Care Delivery & Outcomes

    Novocardia™ Enters Into
    Partnership with MedAxiom™

    Strategic Alliance Focused on Promoting Common Mission of Transforming Quality, Value, and Outcomes of Cardiovascular Care

    Novocardia™ Announces
    Key Additions to Leadership Team
    Accelerating Company’s Mission
    & Growth

    Executives Bring Decades of Multifaceted Health Care Experience that Will Enable Cardiologists to More Successfully Navigate Shifts in Cardiovascular Disease Care
    Contact Us
    200 5th Ave., Suite 4020
    Waltham MA 02451-8704
    Get Novocardia news, events, and innovations delivered right to your inbox.